FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder

FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder DUBLIN, June 1, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with… Read More »

When HIPAA is Outpaced by Technology and the Cyber-Elephant We Need Confront: Exclusive with CEO of VigiTrust

Mathieu Gorge is the author of The Cyber-Elephant in the Boardroom, as well as CEO and founder of VigiTrust, which provides Integrated Risk Management SaaS solutions to clients in 120 countries across various industries. He helps CEOs, CxOs, and boards of directors handle cyber accountability challenges through good cyber hygiene and proactive cybersecurity compliance programs.… Read More »